Results 161 to 170 of about 244,483 (261)

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Drug Utilization Review Board Annual Report 2008-2009

, 2009
New Jersey. Drug Utilization Annual Review Board
core  

The effect of polyallergy on ancillary service use among postoperative patients with gynecologic malignancies. [PDF]

Gynecol Oncol Rep
Coppetti K, Petty M, Walker AR, Alvarado L, Huepenbecker SP, Taylor N, Graul A.   +6 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Drug Utilization Review Board Annual Report 2007-2008

, 2008
New Jersey. Drug Utilization Annual Review Board
core  

Pharmacoepidemiology of antipsychotic utilization among children and adolescents in Montevideo between 2018 and 2022. [PDF]

Front Pharmacol
Cabral S, Catenaccio V, Herrera G, Grunbaum S, Speranza N.   +4 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Drug Utilization Review Board Annual Report 2009-2010

, 2010
New Jersey. Drug Utilization Annual Review Board
core  

Root cause analysis of the challenges to sustain effectiveness of clinical pharmacist-driven antimicrobial stewardship in a Chinese Tertiary Hospital. [PDF]

Front Public Health
Zhao Z, Zhou Y, Li C, Xu J, Xu C, Lu H, Gao Y, Yu B, Shi G, Zhao Y, Li Z, Yang F, Ding P.   +12 more
europepmc   +1 more source